<?xml version="1.0" encoding="UTF-8"?>
<p>Thalassemia major, thalassemia intermedia, and sickle cell disease patients with chronic HCV infection and fibrosis stage of F3â€“F4 were enrolled and then treated with DAAs according to the criteria defined by Italian Medicines Agency and the access to these treatments included a Fibroscan of at least 10 KPa.</p>
